Search results
Results from the WOW.Com Content Network
In the older literature survival rates have been given as 35–50% for stage I–II and 0–15% for stage III and IV uterine papillary serous carcinoma, [4] More recently it was reported that forty-two percent of 138 patients were found disease-free at five years.
Uterine cancer effects approximately 3.1% of females during their lifetime. [8] Uterine cancer resulted in 45,000 deaths worldwide in 1990, with this number increasing to 58,000 deaths in 2010. [21] North America and Northern Europe have the highest rates of uterine cancer.
Uterine clear-cell carcinoma (CC) is a rare form of endometrial cancer with distinct morphological features on pathology; it is aggressive and has high recurrence rate. Like uterine papillary serous carcinoma CC does not develop from endometrial hyperplasia and is not hormone sensitive, rather it arises from an atrophic endometrium.
Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). [1] It is the result of the abnormal growth of cells that have the ability to invade or spread to other parts of the body. [8]
Carcinosarcoma of the uterus. In gross appearance, MMMTs are fleshier than adenocarcinomas, may be bulky and polypoid, and sometimes protrude through the cervical os.On histology, the tumors consist of adenocarcinoma (endometrioid, serous or clear cell) mixed with the malignant mesenchymal elements; alternatively, the tumor may contain two distinct and separate epithelial and mesenchymal ...
C and D. Immunohistochemistry of p53 shows that high-grade serous carcinoma cells are diffusely positive for p53, a pattern consistent with a missense TP53 mutation while the adjacent epithelial cells from the background serous borderline tumor are only focally and weakly positive, a pattern consistent with a wild-type TP53 sequence.
Over a 45-years span — between 1975 and 2020 — improvements in cancer screenings and prevention strategies have reduced deaths from five common cancers more than any advances in treatments ...
Ovarian cancer incidence rates are low in East Asia [56] and highest in Europe, the United States, and Australia/New Zealand. [ 57 ] Since 1975, survival rates for ovarian cancer have steadily improved with a mean decrease of 51% by 2006 of risk of death from ovarian cancer for an advanced stage tumour. [ 58 ]